


## FIIN-3

<b>Cat. No.:</b>	HY-18603		
<b>CAS No.:</b>	1637735-84-2		
<b>Molecular Formula:</b>	C <sub>34</sub> H <sub>36</sub> Cl <sub>2</sub> N <sub>8</sub> O <sub>4</sub>		
<b>Molecular Weight:</b>	691.61		
<b>Target:</b>	EGFR; FGFR		
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 10 mg/mL (14.46 mM; Need ultrasonic and warming)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.4459 mL	7.2295 mL	14.4590 mL
	5 mM	0.2892 mL	1.4459 mL	2.8918 mL
	10 mM	0.1446 mL	0.7230 mL	1.4459 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (3.61 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: 2.5 mg/mL (3.61 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (3.61 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

FIIN-3 is an irreversible inhibitor of FGFR with an IC<sub>50</sub> of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

#### IC<sub>50</sub> & Target

FGFR1	FGFR2	FGFR3	FGFR4
13.1 nM (IC <sub>50</sub> )	21 nM (IC <sub>50</sub> )	31.4 nM (IC <sub>50</sub> )	35.3 nM (IC <sub>50</sub> )

#### In Vitro

FIIN-3 potently inhibits both WT FGFRs (EC<sub>50</sub> in the 1- to 41-nM range) and the gatekeeper mutant of FGFR2 (EC<sub>50</sub> of 64 nM).

---

FIIN-3 also strongly inhibits EGFR, with an EC<sub>50</sub> of 43 nM. FIIN-3 shows good potency against gatekeeper mutant V564F; FIIN-3 also is potent against the gatekeeper-plus-1 mutant E565K; FIIN-3 also displays antiproliferative activity (with an EC<sub>50</sub> of 135 nM) against Ba/F3 cells transformed by the EGFR vIII fusion protein, which has a WT EGFR kinase domain. FIIN-3 shows even better activity against EGFR mutant L858R (EC<sub>50</sub> of 17 nM) and moderate activity, displaying an EC<sub>50</sub> of 231 nM, against the EGFR mutant L858R/T790M mutant. In WT FGFR2 Ba/F3 cells, FIIN-3 completely inhibits the FGFR2 autophosphorylation on Tyr656/657 at concentrations as low as 3 nM. In FGFR2 V564M Ba/F3 cells, FIIN-3 is capable of inhibiting the FGFR2 mutant V564M autophosphorylation with partial inhibition at 100 nM and complete inhibition observed at 300 nM<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## PROTOCOL

### Cell Assay <sup>[1]</sup>

TEL-FGFR2-transformed Ba/F3 cells are seeded in a 96-well plate and are treated with each concentration of FIIN-3. After 72 h the cells are assessed by MTS tetrazolium assay<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

[1]. Tan L et al. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci U S A, 2014 Nov 11, 111(45):E4869-77

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA